The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors

Anti-Cancer Drugs

Volumn 11, Issue 1, 2000, Pages 1-6

  Hartmann, Jörg T ^a   Knop, Stefan ^a   Fels, Lüder M ^a,b,c   Van Vangerow, Anna ^a   Stolte, Hilmar ^a,b,c   Kanz, Lothar ^a   Bokemeyer, Carsten ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Soc for Sci and Technol T   (Germany)

Author keywords

Amifostine; Cisplatin; Hypomagnesemia; Ifosfamide; Nephrotoxicity; Protection

Indexed keywords

ALBUMIN; AMIFOSTINE; CISPLATIN; CREATININE; DEXAMETHASONE; DIURETIC AGENT; ETOPOSIDE; FUROSEMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MANNITOL; MESNA; N ACETYLGLUCOSAMINE; PACLITAXEL;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; ELECTROLYTE EXCRETION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYDRATION; HYPOMAGNESEMIA; MALE; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SOLID TUMOR;

EID: 0034023715     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200001000-00001     Document Type: Article

References (28)

1. 1. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and its possible prevention in patients with testicular cancer. Int J Cancer 1999; 83: 866-9.
2. 2. Daugaard D, Holstein-Rathlou NH, Leyssat PP. Effect of cisplatin on proximal convoluted and straight sequence of the rat kidney. J Pharmacol Exp Ther 1988; 244: 1081-5.
3. 3. Safirstein R, Miller P, Dikman S, et al. Cisplatin nephrotoxicity in rats: defect in papillary hypertonicity. Am J Physiol 1981; 241: 175-85.
4. 4. Clifton GG, Pearce C, O'Neill WM Jr, Wallin JD. Early polyuria in the rat following single-dose cis-dichlorodiam-mineplatinum (II): effects on plasma vasopressin concentration and posterior pituitary function. J Lab Clin Med 1982; 100: 659-70
5. 5. Osanto S, Bukman A, Van Hoek F, et al. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992; 10: 574-9.
6. 6. Treskes M, van-der Vijgh W. WR2721 as a modulator of cisplatin-and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother Pharmacol 1993; 33: 93-106.
7. 7. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12.
8. 8. Bokemeyer, C, Berger, CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14: 2923-32.
9. 9. Glover D, Glick JH, Weiler C, et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986; 4: 584-8.
10. 10. Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 1996; 14: 1913-21.
11. 11. Dorr RT, Holmes BC. Dosing considerations with amifostine: a review of the literature and clinical experience. Semin Oncol 1999; 26 (suppl 7): 108-19.
12. +-cell numbers for PBSC-collection. Proc Am Soc Clin Oncol 1997; 16: 47a (abstr 166).
13. 13. Fetscher S, Brugger W, Engelhardt R, et al. Standard-and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report. Ann Oncol 1999; 10: 561-7.
14. 14. Bradford MM. A rapid and sensitive method for the quantitation of microgramm quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
15. 15. Maruhn D. Rapid colorimetric assay of β-galactosidase and N-acetyl-β-glucosaminidase in human urine. Clin Chim Acta 1976; 73: 453-61.
16. 16. Roth BJ, Einhorn LH, Greist A. Long-term complications of cisplatin-based chemotherapy for testis cancer. Semin Oncol 1988; 15: 345-50.
17. 17. Bissett D, Kunkeler L, Zwanenburg L, et al. Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer 1990; 62: 655-9.
18. 18. Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerulur function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 1988; 21: 163-7.
19. 19. Fjeldborg P, Sorensen J, Helkjaer PE. The long-term effect of cisplatin on renal function. Cancer 1986; 58: 2214-7.
20. 20. Groth S, Nielsen H, Sorensen JB, et al. Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol 1986; 17: 191-6.
21. 21. Hamilton CR, Bliss JM, Horwich A. The late effects of cis-platinum on renal function. Eur J Cancer Clin Oncol 1989; 25: 185-9.
22. 22. Hansen SW, Groth S, Daugaard G, et al. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol 1988; 6: 1728-31.
23. 23. MacLeod PM, Tyrell CJ, Keeling DH. The effect of cisplatin on renal function in patients with testicular tumours. Clin Radiol 1988; 39: 190-2.
24. 24. Moul JW, Robertson JE, George SL, et al. Complications of therapy for testicular cancer. J Urol 1989; 142: 1491-6.
25. 25. Goren MP, Wright RK, Horowitz ME, Pratt CB. Ifosfamide-incluced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 1987; 71: 127-30.
26. 26. Patterson WP, Khojasteh A. Ifosfamide-induced renal tubular defects. Cancer 1989; 63: 649-51.
27. 27. Stuart-Harris RC, Harper PG, Parsons CA, et al. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 1983; 11: 69-72.
28. 28. Marceau D, Poirier M, Masson E, Beaulieu E. High incidence of nephrotoxicity with cisplatin therapy despite adequate hydration: risk factor correlations. Proc Am Soc Clin Oncol 1999; 18: 218a (abstr 840).